Search results
Galectin Therapeutics (NASDAQ:GALT) Upgraded to “Hold” by StockNews.com
ETF DAILY NEWS· 3 days agoGalectin Therapeutics (NASDAQ:GALT – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday. Separately, HC ...
Other countries have better sunscreens. Here's why we can't get them in the U.S.
NPR· 6 days agoEvery hour, at least two people die of skin cancer in the United States. Skin cancer is the most...
Study Finds Radiotherapy for NMSC in Dermatology Growing
Medscape· 3 days agoThe use of radiotherapy has been steadily increasing by dermatologists, according to new findings...
Chemoradiotherapy or RT in Lower Risk Early Cervical Cancer?
Medscape· 2 days agoA study found no significant differences in survival with postoperative chemoradiotherapy vs RT...
Focusing on Treatment Education in Austria this May for Skin Cancer Awareness Month
Digital Journal· 7 days agoOncoBeta® GmbH, a global medical device company specialising in innovative therapies for non-melanoma skin cancers (NMSCs), is supporting World Skin Cancer Awareness Month (May 2024) by focusing ...
Pan-cancer discovery of somatic mutations from RNA sequencing data - Communications Biology
Nature· 1 day agoThe authors develop a web resource to present pan-cancer mutations in 32 major types of cancer. This new online somatic mutations atlas, OncoDB is publicly available at https://oncodb.org .
What’s the truth about sunscreen and cancer?
Consumer Affairs· 4 days agoWith summer beach season about to start, dermatologists are expressing concern about an emerging social media trend. The Wall Street Journal reports one...
Rutgers Cancer Institute and RWJBarnabas Health Set to Unveil Extensive, New Cancer Research...
Benzinga· 8 hours ago49 scheduled presentations will explore several types of cancer, as well as the next frontier of health equity NEW BRUNSWICK, N.J., May 23, 2024 /PRNewswire/ -- Clinicians and scientists from Rutgers Cancer Institute and
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 10 hours agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific antibody, REGN7075 ...
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...
FOX21 Colorado Springs· 11 hours agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company ...